OpenURL Connection Search

Select item for more details and to access through your institution.

Clinical performance and robustness evaluation of plasma amyloid‐β42/40 prescreening.
Published in:
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 4, p. 1393, doi. 10.1002/alz.12801
By:
- Rabe, Christina;
- Bittner, Tobias;
- Jethwa, Alexander;
- Suridjan, Ivonne;
- Manuilova, Ekaterina;
- Friesenhahn, Michel;
- Stomrud, Erik;
- Zetterberg, Henrik;
- Blennow, Kaj;
- Hansson, Oskar
Publication type:
Article
Correction to: Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers.
Published in:
2019
By:
- Rothenberg, Michael E.;
- Tagen, Michael;
- Chang, Jae H.;
- Boyce-Rustay, Janel;
- Friesenhahn, Michel;
- Hackos, David H.;
- Hains, Avis;
- Sutherlin, Dan;
- Ward, Michael;
- Cho, William
Publication type:
Correction Notice
Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers.
Published in:
Clinical Drug Investigation, 2019, v. 39, n. 9, p. 873, doi. 10.1007/s40261-019-00832-2
By:
- Rothenberg, Michael E.;
- Tagen, Michael;
- Chang, Jae H.;
- Boyce-Rustay, Janel;
- Friesenhahn, Michel;
- Hackos, David H.;
- Hains, Avis;
- Sutherlin, Dan;
- Ward, Michael;
- Cho, William
Publication type:
Article
An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: Application to glioblastoma treated with bevacizumab.
Published in:
Magnetic Resonance in Medicine, 2010, v. 63, n. 5, p. 1366, doi. 10.1002/mrm.22335
By:
- Ferl, Gregory Z.;
- Xu, Lu;
- Friesenhahn, Michel;
- Bernstein, Lisa J.;
- Barboriak, Daniel P.;
- Port, Ruediger E.
Publication type:
Article
An Effector-Reduced Anti-&bgr;-Amyloid (A&bgr;) Antibody with Unique A&bgr; Binding Properties Promotes Neuroprotection and Glial Engulfment of A&bgr;.
Published in:
Journal of Neuroscience, 2012, v. 32, n. 28, p. 9677, doi. 10.1523/JNEUROSCI.4742-11.2012
By:
- Adolfsson, Oskar;
- Pihlgren, Maria;
- Toni, Nicolas;
- Varisco, Yvan;
- Buccarello, Anna Lucia;
- Antoniello, Katia;
- Lohmann, Sophie;
- Piorkowska, Kasia;
- Gafner, Valerie;
- Atwal, Jasvinder K.;
- Maloney, Janice;
- Chen, Mark;
- Gogineni, Alvin;
- Weimer, Robby M.;
- Mortensen, Deborah L.;
- Friesenhahn, Michel;
- Ho, Carole;
- Paul, Robert;
- Pfeifer, Andrea;
- Muhs, Andreas
Publication type:
Article

Found: 5

Clinical performance and robustness evaluation of plasma amyloid‐β<sub>42/40</sub> prescreening.

Correction to: Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel Na<sub>V</sub>1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers.

Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel Na<sub>V</sub>1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers.

An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: Application to glioblastoma treated with bevacizumab.

An Effector-Reduced Anti-&bgr;-Amyloid (A&bgr;) Antibody with Unique A&bgr; Binding Properties Promotes Neuroprotection and Glial Engulfment of A&bgr;.